AAP
PLRX icon

Arax Advisory Partners’s Pliant Therapeutics PLRX Stock Holding History

Arax Advisory Partners’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-46
Closed -$606 – 2956
2024
Q4 		$606 Buy
+46
New +$628 ﹤0.01% 2294

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Arax Advisory Partners's PLRX Position: Q1 2025 in Review

Arax Advisory Partners sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 46 shares — an estimated $606 sold.

Arax Advisory Partners first reported a position in PLRX in Q4 2024 and held it in 1 quarter. The position peaked at $606 in Q4 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

  • Arax Advisory Partners reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 46 Pliant Therapeutics shares in Q1 2025, an estimated $606.
  • Arax Advisory Partners first reported a position in Pliant Therapeutics in Q4 2024 and held it in 1 quarter.
  • Arax Advisory Partners's Pliant Therapeutics position peaked at $606 in Q4 2024.
  • 140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Arax Advisory Partners's 13F filing for Q1 2025, filed 15 May 2025.